Effect of egg yolk antibody on experimental infection in mice

Kobayashi, Chizu; Yokoyama, Hisayuki; Nguyen, Sa Van; Kodama, Yoshikatsu; Kimata, Tsutomu; Izeki, Motohiro

doi:10.1016/j.vaccine.2004.05.034

Cited by 27 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exposure of C. parvum to other non-recombinant antibodies has been shown to reduce infection by 60 to 80% in tissue culture assays (Doyle et al 1993;Elliot et al 1997;Kobayashi et al 2004), values less than those presented here. Cevallos et al (2000) demonstrated almost complete inhibition of C. parvum infection in Caco-2 cells with a monoclonal IgM antibody, although the amount of oocysts exposed to the antibodies was unspecified.…”

Section: Discussioncontrasting

confidence: 51%

Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies

Pokorny

Boulter‐Bitzer

Hall

et al. 2008

Antonie van Leeuwenhoek

View full text Add to dashboard Cite

Two phage display antibody libraries (Tomlinson I and J) were screened against the whole oocysts of Cryptosporidium parvum to select for scFv (single chain variable fragment) antibodies. Three scFv antibodies were selected that bound to C. parvum oocysts as determined by monoclonal phage ELISA. DNA sequencing revealed that clone A11 lacked the majority of its V (H) chain. Clone B10 had a stop codon in the first framework region of the V (H) chain. We changed this stop codon to Gly by site-directed mutagenesis, and designated the variant mutB10. Clone B9 had a complete scFv gene with no internal stop codons. These antibody genes were individually subcloned into the pET-20b expression vector for soluble scFv antibody production. C. parvum infectivity was determined by infection of HCT-8 tissue culture monolayers and quantified by the foci detection method. By incubating C. parvum oocysts with individual scFv antibodies for 1 h at 37 degrees C prior to infecting the HCT-8 cells with the oocyst-scFv mixture, the infectivity of C. parvum was reduced in a dose-dependent manner. At the highest soluble scFv concentration tested (4 nmol), the mean number of infectious foci was reduced by 82%, 73% and 94% for the A11, B9 and mutB10 scFv, respectively. This inhibition of oocyst infectivity was abolished when the scFvs were exposed to boiling water. The results showed that the 3 selected scFvs bound to C. parvum oocysts, and their ability to neutralize infectivity may have potential therapeutic potential against cryptosporidiosis.

show abstract

Section: Discussioncontrasting

confidence: 51%

Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies

Pokorny

Boulter‐Bitzer

Hall

et al. 2008

Antonie van Leeuwenhoek

View full text Add to dashboard Cite

show abstract

“…IgY has potential as an oral immunotherapy against several types of microbes [11][12][13][14]. Specific antibodies are produced by immunization of hens and purification of antibodies from the yolk of their eggs.…”

Section: Introductionmentioning

confidence: 99%

Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin

Nilsson

Ahmad

Wretlind

et al. 2007

Journal of Chromatography B

View full text Add to dashboard Cite

“…Oral administration of IgY antibodies has been tested for many years with promising results [80] to different pathogens as human rotavirus [81]; dental plaque formation by Streptococcus mutans [82,83]; enteropathogenic E. coli [84]; Helicobacter pylori [85,86]; Cryptosporidium parvum [87,88]; canine parvovirus [89]; Porphyromonas gingivalis [90]; Pseudomonas aeruginosa [91]; shrimp's white spot syndrome virus [92]; Eimeria acervulina [93]; E. tenella and E. maxima [94,95]; H5N1 e H1N1 in mice [96]; Vibrio cholerae [97]; rotavirus and norovirus [98]; Campylobacter jejuni [99][100][101]; and botulinum neurotoxins [102]. Immunotherapy as a passive immunization method to neutralize venom using purified IgY proved to be efficient for therapy protocol [103][104][105][106][107].…”

Section: Using Igy For Passive Immunizationmentioning

confidence: 99%

IgY-Technology Applied to Studies of Toxoplasma gondii Infection

Júnior¹,

Santos²,

Bassi³

et al. 2017

Toxoplasmosis

View full text Add to dashboard Cite

In this chapter, we describe relevant aspects of immunoglobulin Y (IgY) technology for Toxoplasma gondii applications, including comparison of avian IgY antibody with mammalian IgG antibody, egg yolk IgY production and isolation procedures, important applications for IgY antibody, and state of the art and perspectives for IgY-technology in T. gondii studies. T. gondii is a worldwide public health problem. IgY-technology provides an alternative antibody (IgY) to mammalian Immunoglobulin G (IgG) antibody. IgY-technology involves the chicken immunization, yolk IgY isolation, antibody characterization, and purified IgY application to several kinds of methods. Immunized chicken transfers a specific IgY from blood to egg yolk. Phylogenetic distance between chickens and mammals influences the generation of antibody repertoires recognizing an antigen profile. IgY is not bound to rheumatoid factor or mammalian complement protein and thus avoids the false-positive results. Yolk IgY isolation is carried out by simple procedures that are accessible for any laboratory and, also, for IgY isolation at large-scale production. IgY-technology provides antibodies for proteomic studies, diagnostic assays, and immunotherapy. Although IgY-technology is promising, there is a reduced number of investigations with IgY and T. gondii. Future perspectives involve the use of IgY-technology for the screening of new T. gondii antigens for diagnostics, therapy, or vaccine, development of innovative techniques for toxoplasmosis diagnostics and may be an immunotherapy for toxoplasmosis.

show abstract

Effect of egg yolk antibody on experimental infection in mice

Cited by 27 publications

References 14 publications

Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies

Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies

Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin

IgY-Technology Applied to Studies of Toxoplasma gondii Infection

Contact Info

Product

Resources

About